2,986 results match your criteria Breast cancer research : BCR[Journal]


Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.

Breast Cancer Res 2020 Jun 30;22(1):73. Epub 2020 Jun 30.

Computational Biology Laboratory, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark.

Background: Studies on tumor-secreted microRNAs point to a functional role of these in cellular communication and reprogramming of the tumor microenvironment. Uptake of tumor-secreted microRNAs by neighboring cells may result in the silencing of mRNA targets and, in turn, modulation of the transcriptome. Studying miRNAs externalized from tumors could improve cancer patient diagnosis and disease monitoring and help to pinpoint which miRNA-gene interactions are central for tumor properties such as invasiveness and metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01295-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329449PMC

PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.

Breast Cancer Res 2020 Jun 29;22(1):72. Epub 2020 Jun 29.

Division of Hematology and Medical Oncology, Department of Medicine, New York, USA.

Background: Protein kinase C theta, (PRKCQ/PKCθ) is a serine/threonine kinase that is highly expressed in a subset of triple-negative breast cancers (TNBC) and promotes their growth, anoikis resistance, epithelial-mesenchymal transition (EMT), and invasion. Here, we show that PRKCQ regulates the sensitivity of TNBC cells to apoptosis triggered by standard-of-care chemotherapy by regulating levels of pro-apoptotic Bim.

Methods: To determine the effects of PRKCQ expression on chemotherapy-induced apoptosis, shRNA and cDNA vectors were used to modulate the PRKCQ expression in MCF-10A breast epithelial cells or triple-negative breast cancer cells (MDA-MB231Luc, HCC1806). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01302-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322866PMC

Correction to: FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.

Breast Cancer Res 2020 Jun 29;22(1):71. Epub 2020 Jun 29.

Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.

An amendment to this paper has been published and can be accessed via the original article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01310-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322869PMC

Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology.

Breast Cancer Res 2020 Jun 26;22(1):70. Epub 2020 Jun 26.

University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Background: Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to form these ophthalmic metastases (OM) more frequently than invasive ductal carcinomas (IDC). We herein report our single academic institution experience with breast cancer OM with respect to anatomical presentation, histology (lobular vs. ductal), treatment, and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01309-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318761PMC

New generation breast cancer cell lines developed from patient-derived xenografts.

Breast Cancer Res 2020 Jun 23;22(1):68. Epub 2020 Jun 23.

Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.

Background: Breast cancer is a highly heterogeneous disease characterized by multiple histologic and molecular subtypes. While a myriad of breast cancer cell lines have been developed over the past 60 years, estrogen receptor alpha (ER)+ disease and some mutations associated with this subtype remain underrepresented. Here we describe six breast cancer cell lines derived from patient-derived xenografts (PDX) and their general characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01300-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310532PMC

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.

Breast Cancer Res 2020 Jun 23;22(1):69. Epub 2020 Jun 23.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Unit 85, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Background: In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff values across tumor types are lacking. Data on how different scoring methods compare in breast cancer are scant.

Methods: Using FDA-approved 22C3 diagnostic immunohistochemistry assay, we retrospectively evaluated PD-L1 expression in 496 primary invasive breast tumors that were not exposed to anti-PD-1/PD-L1 treatment and compared three scoring methods (TC: invasive tumor cells; IC: tumor-infiltrating immune cells; TCIC: a combination of tumor cells and immune cells) in expression frequency and association with clinicopathologic factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01303-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310491PMC

Effects of tumor-specific CAP1 expression and body constitution on clinical outcomes in patients with early breast cancer.

Breast Cancer Res 2020 Jun 19;22(1):67. Epub 2020 Jun 19.

Department of Clinical Sciences Lund, Oncology, Skåne University Hospital, Lund University, Lund, Sweden.

Background: Obesity induces molecular changes that may favor tumor progression and metastatic spread, leading to impaired survival outcomes in breast cancer. Adenylate cyclase-associated protein 1 (CAP1), an actin regulatory protein and functional receptor for the obesity-associated adipokine resistin, has been implicated with inferior cancer prognosis. Here, the objective was to investigate the interplay between body composition and CAP1 tumor expression regarding breast cancer outcome through long-term survival analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01307-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304201PMC

KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.

Breast Cancer Res 2020 Jun 18;22(1):66. Epub 2020 Jun 18.

Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA.

Background: Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therapeutically targetable driver pathways of this disease. While epidermal growth factor receptor (EGFR) is expressed in 60% of TNBCs and drives disease progression, attempts to inhibit EGFR in unselected TNBC patients have had a marginal impact on outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01305-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301986PMC

Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer.

Breast Cancer Res 2020 Jun 17;22(1):65. Epub 2020 Jun 17.

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

Background: Crown-like structures in breast adipose tissue (CLS-B), composed of necrotic adipocytes encircled by macrophages, are associated with obesity and hypothesized to worsen breast cancer prognosis; however, data are sparse, particularly in multi-racial populations.

Methods: We assessed specimens for CLS-B from 174 African-American and 168 White women with stage I-III breast cancer treated by mastectomy. Benign breast tissue from an uninvolved quadrant was immunohistochemically stained for CD68 to determine CLS-B presence and density (per cm of adipose tissue). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01308-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298873PMC

Age-associated genes in human mammary gland drive human breast cancer progression.

Breast Cancer Res 2020 Jun 15;22(1):64. Epub 2020 Jun 15.

Department of Cell Systems & Anatomy, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Background: Aging is a comorbidity of breast cancer suggesting that aging-associated transcriptome changes may promote breast cancer progression. However, the mechanism underlying the age effect on breast cancer remains poorly understood.

Method: We analyzed transcriptomics of the matched normal breast tissues from the 82 breast cancer patients in The Cancer Genome Atlas (TCGA) dataset with linear regression for genes with age-associated expression that are not associated with menopause. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01299-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294649PMC

Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.

Breast Cancer Res 2020 Jun 11;22(1):63. Epub 2020 Jun 11.

The Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia.

Background: Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01306-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291584PMC

Triple-negative breast cancer molecular subtyping and treatment progress.

Breast Cancer Res 2020 Jun 9;22(1):61. Epub 2020 Jun 9.

Department of Stem Cell and Regenerative Medicine, Southwest Hospital, Third Military Medical University (Army Medical University), ChongQing, 400038, China.

Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01296-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285581PMC

Racial differences in CD8 T cell infiltration in breast tumors from Black and White women.

Breast Cancer Res 2020 Jun 9;22(1):62. Epub 2020 Jun 9.

Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Background: African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been reported between Black and White women, and the tumor immune milieu could potentially drive racial differences in breast cancer etiology and outcome.

Methods: We examined the association of CD8 cytotoxic T cells with clinical-pathological variables in the Women's Circle of Health Study (WCHS) population of predominantly Black breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01297-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285742PMC

Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer.

Breast Cancer Res 2020 Jun 5;22(1):60. Epub 2020 Jun 5.

Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.

Background: Mitochondrial dynamics underlies malignant transformation, cancer progression, and response to treatment. Current research presents conflicting evidence for functions of mitochondrial fission and fusion in tumor progression. Here, we investigated how mitochondrial fission and fusion states regulate underlying processes of cancer progression and metastasis in triple-negative breast cancer (TNBC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01301-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275541PMC

FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.

Breast Cancer Res 2020 Jun 3;22(1):59. Epub 2020 Jun 3.

Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.

Background: Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast cancer is the most aggressive subtype with limited treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01298-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268629PMC

Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer.

Breast Cancer Res 2020 May 28;22(1):58. Epub 2020 May 28.

Breast Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: Ultrafast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-derived kinetic parameters have demonstrated at least equivalent accuracy to standard DCE-MRI in differentiating malignant from benign breast lesions. However, it is unclear if they have any efficacy as prognostic imaging markers. The aim of this study was to investigate the relationship between ultrafast DCE-MRI-derived kinetic parameters and breast cancer characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01292-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254650PMC

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.

Breast Cancer Res 2020 May 28;22(1):56. Epub 2020 May 28.

Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.

Background: Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting. We aimed to prospectively compare the risk of early progression according to circulating ESR1 mutations, CA-15. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01290-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254698PMC

A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy.

Breast Cancer Res 2020 May 28;22(1):57. Epub 2020 May 28.

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: For breast cancer patients undergoing neoadjuvant chemotherapy (NAC), pathologic complete response (pCR; no invasive or in situ) cannot be assessed non-invasively so all patients undergo surgery. The aim of our study was to develop and validate a radiomics classifier that classifies breast cancer pCR post-NAC on MRI prior to surgery.

Methods: This retrospective study included women treated with NAC for breast cancer from 2014 to 2016 with (1) pre- and post-NAC breast MRI and (2) post-NAC surgical pathology report assessing response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01291-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254668PMC

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.

Breast Cancer Res 2020 05 28;22(1):55. Epub 2020 May 28.

UVSQ, Université Paris-Saclay, Saint Cloud, France.

Background: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France).

Methods: An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01293-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254663PMC

Modeling the natural history of ductal carcinoma in situ based on population data.

Breast Cancer Res 2020 May 27;22(1):53. Epub 2020 May 27.

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

Background: The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the absence of biopsy or complete excision.

Methods: Two well-established population models evaluated six possible DCIS natural history submodels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01287-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251719PMC

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.

Breast Cancer Res 2020 May 27;22(1):54. Epub 2020 May 27.

Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, South Korea.

Introduction: Neoadjuvant endocrine therapy (NET) has demonstrated efficacy in post-menopausal patients with hormone-responsive breast cancer. This trial was designed to compare the efficacy of neoadjuvant chemotherapy (NCT) with NET in pre-menopausal breast cancer.

Patients And Methods: In this prospective, randomised, phase III study, oestrogen receptor (ER)-positive, HER2-negative, and lymph node-positive pre-menopausal breast cancer patients were recruited from 7 hospitals in South Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01288-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251809PMC

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Breast Cancer Res 2020 May 20;22(1):52. Epub 2020 May 20.

The Methodist Hospital Research Institute, 6445 Main Street, Houston, TX, 77030, USA.

An amendment to this paper has been published and can be accessed via the original article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01294-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238734PMC

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.

Breast Cancer Res 2020 May 19;22(1):51. Epub 2020 May 19.

Department of Oncology, Mayo Clinic, Rochester, MN, USA.

Background: The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase expressing model (MCF7AC1), as well as with tamoxifen, fulvestrant, exemestane, and exemestane plus everolimus in a letrozole-resistant MCF7 model (MCF7LR).

Methods: MCF7AC1 tumor-bearing mice were randomized to control (no drug), letrozole (10 μg/day), tamoxifen (500 μg/day), or Z-endoxifen (25 and 75 mg/kg). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01286-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238733PMC

ERα-36 regulates progesterone receptor activity in breast cancer.

Breast Cancer Res 2020 May 19;22(1):50. Epub 2020 May 19.

Université de Lyon, F-69000, Lyon, France.

Background: Alterations in estrogen and progesterone signaling, via their respective receptors, estrogen receptor alpha (ERα) and progesterone receptor (PR), respectively, are largely involved in the development of breast cancer (BC). The recent identification of ERα-36, a splice variant of ERα, has uncovered a new facet of this pathology. Although ERα-36 expression is associated with poor prognosis, metastasis development, and resistance to treatment, its predictive value has so far not been associated with a BC subtype and its mechanisms of action remain understudied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01278-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238515PMC

Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients.

Breast Cancer Res 2020 May 15;22(1):49. Epub 2020 May 15.

Department of Molecular Oncology, King Faisal Specialist Hospital and Research Center, MBC#03, Riyadh, 11211, Saudi Arabia.

Background: Most breast cancer-associated fibroblasts (CAFs) are active and important cancer-promoting cells, with significant impact on patient prognosis. Therefore, we investigated here the role of the protein kinase ATR in breast stromal fibroblasts in the prognosis of locally advanced breast cancer patients.

Methods: We have used immunohistochemistry to assess the level of ATR in breast cancer tissues and their adjacent normal tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01289-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229635PMC

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.

Breast Cancer Res 2020 May 15;22(1):48. Epub 2020 May 15.

Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, 77030, USA.

Background: The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contribute to the survival and development of resistance in response to therapy. This study investigated the effects of Pan-HER (Symphogen, Ballerup, Denmark), a novel mixture of six monoclonal antibodies directed against members of the HER family EGFR, HER2, and HER3, in a preclinical trial of TNBC patient-derived xenografts (PDXs).

Methods: Fifteen low passage TNBC PDX tumor samples were transferred into the right mammary fat pad of mice for engraftment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01280-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227035PMC

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.

Breast Cancer Res 2020 May 14;22(1):46. Epub 2020 May 14.

Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark.

Background: The presence of tumour-infiltrating lymphocytes (TILs) is associated with response to neoadjuvant chemotherapy among patients with triple-negative and HER2-positive breast cancer. However, the significance of TILs is less clear in luminal breast cancer. Here, we in postmenopausal patients with primary oestrogen receptor-positive (ER+), HER2 normal, operable breast cancer assessed the importance of inducing TILs during 4 months of letrozole on response in a neoadjuvant phase II study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01285-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222485PMC

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.

Breast Cancer Res 2020 May 14;22(1):47. Epub 2020 May 14.

West German Study Group, Mönchengladbach, Germany.

Background: The presence of tumor-infiltrating lymphocytes has been associated with prognosis and chemotherapy response, particularly in high-risk breast cancer subtypes. There is limited data so far as to (i) how tumor-infiltrating lymphocyte (TIL) measurements correlate with genomic measurements such as the Oncotype DX Recurrence Score® and (ii) whether the survival impact of TIL measurements varies according to different adjuvant systemic therapies.

Methods: The WSG PlanB trial compared an anthracycline-free chemotherapy regimen (6x docetaxel/cyclophosphamide, TC) to an anthracycline-taxane sequence (4xEC followed by 4x docetaxel) in patients with intermediate-risk, HER2-negative early breast cancer (EBC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01283-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227091PMC

Frequency and spectrum of PIK3CA somatic mutations in breast cancer.

Breast Cancer Res 2020 May 13;22(1):45. Epub 2020 May 13.

Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.

Purpose: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations in BC. This information is critical as patients and clinicians are using this and other genomic assays to indicate alpelisib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01284-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222307PMC

Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay.

Breast Cancer Res 2020 May 11;22(1):43. Epub 2020 May 11.

Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Bldg 560, Room 32-33, 1050 Boyles Street, Frederick, MD, 21702, USA.

Next-generation sequencing of Sri Lankan families with inherited cancer syndromes resulted in the identification of five BRCA2 variants of unknown clinical significance. Interpreting such variants poses significant challenges for both clinicians and patients. Using a mouse embryonic stem cell-based functional assay, we found I785V, N830D, and K2077N to be functionally indistinguishable from wild-type BRCA2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01272-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216543PMC

Insulin resistance contributes to racial disparities in breast cancer prognosis in US women.

Breast Cancer Res 2020 May 12;22(1):40. Epub 2020 May 12.

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Background: Racial disparities in breast cancer survival between Black and White women persist across all stages of breast cancer. The metabolic syndrome (MetS) of insulin resistance disproportionately affects more Black than White women. It has not been discerned if insulin resistance mediates the link between race and poor prognosis in breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01281-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216707PMC

Investigation of the adolescent female breast transcriptome and the impact of obesity.

Breast Cancer Res 2020 May 11;22(1):44. Epub 2020 May 11.

Clinical Research Branch, National Institute of Environmental Health Sciences, 111 TW Alexander Drive, MD A2-03, Research Triangle Park, NC, 27709, USA.

Background: Early life environmental exposures affect breast development and breast cancer risk in adulthood. The breast is particularly vulnerable during puberty when mammary epithelial cells proliferate exponentially. In overweight/obese (OB) women, inflammation increases breast aromatase expression and estrogen synthesis and promotes estrogen-receptor (ER)-positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01279-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216667PMC

Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients.

Breast Cancer Res 2020 May 6;22(1):42. Epub 2020 May 6.

Division of Pathology, Singapore General Hospital, 20 College Road, Academia, Level 7, Diagnostics Tower, Singapore, 169856, Singapore.

Background: Stromal and collagen biology has a significant impact on tumorigenesis and metastasis. Collagen is a major structural extracellular matrix component in breast cancer, but its role in cancer progression is the subject of historical debate. Collagen may represent a protective layer that prevents cancer cell migration, while increased stromal collagen has been demonstrated to facilitate breast cancer metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01282-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204022PMC

In utero estrogenic endocrine disruption alters the stroma to increase extracellular matrix density and mammary gland stiffness.

Breast Cancer Res 2020 May 5;22(1):41. Epub 2020 May 5.

Department of Molecular Genetics, The Ohio State University, 920 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA.

Background: In utero endocrine disruption is linked to increased risk of breast cancer later in life. Despite numerous studies establishing this linkage, the long-term molecular changes that predispose mammary cells to carcinogenic transformation are unknown. Herein, we investigated how endocrine disrupting compounds (EDCs) drive changes within the stroma that can contribute to breast cancer susceptibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01275-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201668PMC

Glucocorticoid receptors are required effectors of TGFβ1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer.

Breast Cancer Res 2020 May 1;22(1):39. Epub 2020 May 1.

Departments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota Masonic Cancer Center, Delivery Code 2812 Cancer and Cardiovascular Research Building; Suite 3-126 2231 6th St SE, Minneapolis, MN, 55455, USA.

Background: Altered signaling pathways typify breast cancer and serve as direct inputs to steroid hormone receptor sensors. We previously reported that phospho-Ser134-GR (pS134-GR) species are elevated in triple-negative breast cancer (TNBC) and cooperate with hypoxia-inducible factors, providing a novel avenue for activation of GR in response to local or cellular stress.

Methods: We probed GR regulation by factors (cytokines, growth factors) that are rich within the tumor microenvironment (TME). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01277-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193415PMC

Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells.

Breast Cancer Res 2020 Apr 22;22(1):38. Epub 2020 Apr 22.

INSERM N2C UMR1069, University of Tours, 37032, Tours, France.

Background: The highest incidence of breast cancer is in the Western world. Several aspects of the Western lifestyle are known risk factors for breast cancer. In particular, previous studies have shown that cholesterol levels can play an important role in the regulation of tumor progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01276-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178965PMC

Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.

Breast Cancer Res 2020 Apr 15;22(1):36. Epub 2020 Apr 15.

Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.

Background: Multigene panels are routinely used to assess for predisposing germline mutations in families at high breast cancer risk. The number of variants of unknown significance thereby identified increases with the number of sequenced genes. We aimed to determine whether tumor sequencing can help refine the analysis of germline variants based on second somatic genetic events in the same gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01273-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161277PMC

Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.

Breast Cancer Res 2020 Apr 15;22(1):37. Epub 2020 Apr 15.

Department of Oncology, Karmanos Cancer Institute Wayne State University, 4100 John R Street, Detroit, MI, 48201, USA.

Background: At least 50% of triple negative breast cancer (TNBC) overexpress the epidermal growth factor receptor, EGFR, which paved the way for clinical trials investigating its blockade. Outcomes remained dismal stemming from mechanisms of resistance particularly the nuclear cycling of EGFR, which is enhanced by Src activation. Attenuation of Src reversed nuclear translocation, restoring EGFR to the cell surface. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01270-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160960PMC

Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.

Breast Cancer Res 2020 Mar 23;22(1):31. Epub 2020 Mar 23.

Department of Microbiology, Immunology and Genetics, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX, 76107, USA.

After publication of the original article [1], we were notified that the wrong version of Fig. 2b has been published. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01268-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087376PMC

Letter to the editor: Response to Giardiello D, Antoniou AC, Mariani L, Easton DF, Steyerberg EW.

Breast Cancer Res 2020 Apr 10;22(1):35. Epub 2020 Apr 10.

Department of Clinical Research, Faculty of Medicine, University of Basel, Missionstrasse 64, 2 OG - Room 007, 4055, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01274-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146948PMC

Breast cancer bone metastases are attenuated in a Tgif1-deficient bone microenvironment.

Breast Cancer Res 2020 Apr 9;22(1):34. Epub 2020 Apr 9.

Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Background: Osteoclast activation is a hallmark of breast cancer-induced bone disease while little is known about the role of osteoblasts in this process. Recently, we identified the homeodomain protein TG-interacting factor-1 (Tgif1) as a crucial regulator of osteoblast function. In this study, we demonstrate that lack of Tgif1 also restricts the progression of breast cancer bone metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01269-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146874PMC

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.

Breast Cancer Res 2020 04 6;22(1):33. Epub 2020 Apr 6.

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133, Milan, Italy.

Background: The PI3K/AKT/mTORC1 axis is implicated in hormone receptor-positive HER2-negative metastatic breast cancer (HR+ HER2- mBC) resistance to anti-estrogen treatments. Based on results of the BOLERO-2 trial, the mTORC1 inhibitor everolimus in combination with the steroidal aromatase inhibitor (AI) exemestane has become a standard treatment for patients with HR+ HER2- mBC resistant to prior non-steroidal AI therapy. In the recent SOLAR-1 trial, the inhibitor of the PI3K alpha subunit (p110α) alpelisib in combination with fulvestrant prolonged progression-free survival (PFS) when compared to fulvestrant alone in patients with PIK3CA-mutated HR+ HER2- mBC that progressed after/on previous AI treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01271-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137211PMC

Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.

Breast Cancer Res 2020 03 26;22(1):32. Epub 2020 Mar 26.

Department of Pathology, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.

Background: The immune microenvironment in ductal carcinoma in situ (DCIS) and its significance are not well established. This study was conducted to evaluate the immune microenvironment of DCIS including the composition of tumor-infiltrating lymphocyte (TIL) subsets and PD-L1+ immune cells and to compare it with that of invasive breast cancer.

Materials And Methods: A total of 671 cases including three different disease groups of pure DCIS, DCIS with microinvasion (DCIS-M), and invasive carcinoma were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01267-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098119PMC

High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer.

Breast Cancer Res 2020 03 18;22(1):30. Epub 2020 Mar 18.

Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.

Background: Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight may improve male breast cancer management. The hepatocyte growth factor (HGF)/c-MET axis and the stromal cell-derived factor-1 (CXCL12)/C-X-C chemokine receptor type 4 (CXCR4) axis are prognostic in women with breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01266-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081628PMC

Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.

Breast Cancer Res 2020 03 13;22(1):29. Epub 2020 Mar 13.

Department of Biomedical Engineering, Boston University, 44 Cummington Mall, Boston, MA, 02215, USA.

Background: Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy. This demonstrates the need for techniques capable of providing personalized feedback about treatment response at the earliest stages of therapy to identify patients likely to benefit from changing treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01262-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071774PMC

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.

Breast Cancer Res 2020 03 12;22(1):27. Epub 2020 Mar 12.

David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.

Background: Palbociclib improves outcomes for women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC). Dose reductions are recommended for the management of hematologic toxicities. A previous pooled analysis from the PALOMA clinical trials showed that 36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01263-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068918PMC

Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.

Breast Cancer Res 2020 03 12;22(1):28. Epub 2020 Mar 12.

The Dr. Pinchas Borenstein Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Ramat Gan, Israel.

After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients' codes are listed, was cropped by mistake so the patients 1-8 are repeated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01265-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068888PMC

MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.

Breast Cancer Res 2020 03 6;22(1):26. Epub 2020 Mar 6.

Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, 87 Ding Jiaqiao Rd., Nanjing, 210009, China.

Background: Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through mechanisms that remain unknown.

Methods: We examined miR-7 expression in breast cancer and developed a BCSC-driven xenograft mouse model, to evaluate the effects of miR-7 overexpression on the decrease of the BCSC subset in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01264-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060548PMC

Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.

Breast Cancer Res 2020 Feb 26;22(1):25. Epub 2020 Feb 26.

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, CBI 8RN, UK.

After publication of the original article [1], we were notified that columns in Table 2 were erroneously displayed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01259-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045606PMC
February 2020

Lower vitamin D status may help explain why black women have a higher risk of invasive breast cancer than white women.

Authors:
William B Grant

Breast Cancer Res 2020 02 21;22(1):24. Epub 2020 Feb 21.

Sunlight, Nutrition, and Health Research Center, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01261-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033921PMC
February 2020